health

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

TL;DR

  • Novartis is acquiring Excellergy for up to $2 billion to add a next-generation allergy treatment to its portfolio.
  • The deal aims to bolster Novartis' pipeline as it faces significant patent expirations on key drugs like Entresto and Cosentyx.
  • This is Novartis' second multi-billion dollar acquisition in a week, following the deal for Pikavation Therapeutics.
  • Excellergy's lead drug candidate, Exl-111, is still in early stages of development.
  • The pharmaceutical industry, including companies like Merck, GSK, and AstraZeneca, is seeing a wave of M&A activity to address the 'patent cliff'.

Continuar leyendo el artículo original